Immunogenicity of a fractional or full third dose of AZD1222 vaccine or BNT162b2 messenger RNA vaccine after two doses of CoronaVac vaccines against the Delta and Omicron variants.
Immunogenicity of a fractional or full third dose of AZD1222 vaccine or BNT162b2 messenger RNA vaccine after two doses of CoronaVac vaccines against the Delta and Omicron variants.
复制标题
DOI：
10.1016/j.ijid.2023.01.022
复制
发表时间：
2023-04
影响因子：
8.4
通讯作者：
Pitisuttithum, Punnee
中科院分区：
文献类型：
--
作者：
Niyomnaitham, Suvimol;Jongkaewwattana, Anan;Meesing, Atibordee;Pinpathomrat, Nawamin;Nanthapisal, Sira;Hirankarn, Nattiya;Siwamogsatham, Sarawut;Kirdlarp, Suppachok;Chaiwarith, Romanee;Lawpoolsri, Saranath;Phanthanawiboon, Supranee;Thitithanyanont, Arunee;Hansasuta, Pokrath;Chaiyaroj, Sansanee;Pitisuttithum, Punnee
该研究旨在比较两剂 CoronaVac 后以及在三个不同的延长间隔后加强接种时，部分（半）第三剂异源 COVID-19 疫苗（AZD1222 或 BNT162b2）与全剂量的免疫原性和安全性。在两次剂量 CoronaVac 后的 60-<90、90-<120 或 120-180 天间隔内，参与者被随机分配至全剂量或半剂量 AZD1222 或 BNT162b2，并在第 28、60 和 90 天进行随访。通过以下方法评估疫苗诱导的对 Ancestral、Delta 和 Omicron BA.1 菌株的免疫反应抗尖峰、假病毒、微中和和 T 细胞测定。描述性统计和非劣效性截止值报告为几何平均浓度或效价以及浓度或效价比，比较基线与第28天和第90天以及不同时间间隔。没有发现任何安全问题。所有测定和间隔均显示全剂量和半剂量之间的免疫原性不差。然而，全剂量疫苗和/或更长的 120-180 天间隔显着改善了免疫原性（通过抗尖峰测量或通过假型病毒中和滴度 50 测量；P <0.001）。所有检测结果显示，针对 SARS-CoV-2 毒株的血清转化率均超过 90%。半剂量比全剂量的免疫原性减弱得更快，但针对 Ancestral 或 Delta 菌株的免疫原性仍然很高。针对 Omicron，第 28 天的免疫原性随着间隔时间的延长而增加，而全剂量疫苗的间隔时间较短。在两剂 CoronaVac 后以较长间隔进行加强时，第 28 天后的免疫反应是最佳的。通过所有评估的免疫测定，与全剂量相比，半剂量符合非劣效性标准。
The study aimed to compare the immunogenicity and safety of fractional (half) third doses of heterologous COVID-19 vaccines (AZD1222 or BNT162b2) to full doses after the two-dose CoronaVac and when boosting after three different extended intervals. At 60-<90, 90-<120, or 120-180 days intervals after the two-dose CoronaVac, participants were randomized to full-dose or half-dose AZD1222 or BNT162b2, followed up at day 28, 60, and 90. Vaccination-induced immune responses to Ancestral, Delta, and Omicron BA.1 strains were evaluated by antispike, pseudovirus, and microneutralization and T cell assays. Descriptive statistics and noninferiority cut-offs were reported as geometric mean concentration or titer and concentration or titer ratios comparing baseline to day 28 and day 90 and different intervals. No safety concerns were detected. All assays and intervals showed noninferior immunogenicity between full doses and half doses. However, full-dose vaccines and/or longer 120-180-day intervals substantially improved the immunogenicity (measured by antispike or measured by pseudotyped virus neutralizing titers 50; P <0.001). Seroconversion rates were over 90% against the SARS-CoV-2 strains by all assays. Immunogenicity waned more quickly with half doses than full doses but remained high against the Ancestral or Delta strains. Against Omicron, the day 28 immunogenicity increased with longer intervals than shorter intervals for full-dose vaccines. Immune responses after day 28 when boosting at longer intervals after the two-dose CoronaVac was optimal. Half doses met the noninferiority criteria compared with the full dose by all the immune assays assessed.
登录
查看更多内容
DOI：
10.1016/s0140-6736(20)32661-1
发表时间：
2021-01-09
期刊：
Lancet (London, England)
影响因子：
--
作者：
Voysey M;Clemens SAC;Madhi SA;Weckx LY;Folegatti PM;Aley PK;Angus B;Baillie VL;Barnabas SL;Bhorat QE;Bibi S;Briner C;Cicconi P;Collins AM;Colin-Jones R;Cutland CL;Darton TC;Dheda K;Duncan CJA;Emary KRW;Ewer KJ;Fairlie L;Faust SN;Feng S;Ferreira DM;Finn A;Goodman AL;Green CM;Green CA;Heath PT;Hill C;Hill H;Hirsch I;Hodgson SHC;Izu A;Jackson S;Jenkin D;Joe CCD;Kerridge S;Koen A;Kwatra G;Lazarus R;Lawrie AM;Lelliott A;Libri V;Lillie PJ;Mallory R;Mendes AVA;Milan EP;Minassian AM;McGregor A;Morrison H;Mujadidi YF;Nana A;O'Reilly PJ;Padayachee SD;Pittella A;Plested E;Pollock KM;Ramasamy MN;Rhead S;Schwarzbold AV;Singh N;Smith A;Song R;Snape MD;Sprinz E;Sutherland RK;Tarrant R;Thomson EC;Török ME;Toshner M;Turner DPJ;Vekemans J;Villafana TL;Watson MEE;Williams CJ;Douglas AD;Hill AVS;Lambe T;Gilbert SC;Pollard AJ;Oxford COVID Vaccine Trial Group
通讯作者：
Oxford COVID Vaccine Trial Group
DOI：
10.1016/s0140-6736(21)00432-3
发表时间：
2021-03-06
期刊：
Lancet (London, England)
影响因子：
--
作者：
Voysey M;Costa Clemens SA;Madhi SA;Weckx LY;Folegatti PM;Aley PK;Angus B;Baillie VL;Barnabas SL;Bhorat QE;Bibi S;Briner C;Cicconi P;Clutterbuck EA;Collins AM;Cutland CL;Darton TC;Dheda K;Dold C;Duncan CJA;Emary KRW;Ewer KJ;Flaxman A;Fairlie L;Faust SN;Feng S;Ferreira DM;Finn A;Galiza E;Goodman AL;Green CM;Green CA;Greenland M;Hill C;Hill HC;Hirsch I;Izu A;Jenkin D;Joe CCD;Kerridge S;Koen A;Kwatra G;Lazarus R;Libri V;Lillie PJ;Marchevsky NG;Marshall RP;Mendes AVA;Milan EP;Minassian AM;McGregor A;Mujadidi YF;Nana A;Padayachee SD;Phillips DJ;Pittella A;Plested E;Pollock KM;Ramasamy MN;Ritchie AJ;Robinson H;Schwarzbold AV;Smith A;Song R;Snape MD;Sprinz E;Sutherland RK;Thomson EC;Török ME;Toshner M;Turner DPJ;Vekemans J;Villafana TL;White T;Williams CJ;Douglas AD;Hill AVS;Lambe T;Gilbert SC;Pollard AJ;Oxford COVID Vaccine Trial Group
通讯作者：
Oxford COVID Vaccine Trial Group
DOI：
10.1056/nejmoa2201570
发表时间：
2022-05-05
期刊：
The New England journal of medicine
影响因子：
--
作者：
通讯作者：
--
影响因子：
5.5
作者：
Patel MK;Bergeri I;Bresee JS;Cowling BJ;Crowcroft NS;Fahmy K;Hirve S;Kang G;Katz MA;Lanata CF;L'Azou Jackson M;Joshi S;Lipsitch M;Mwenda JM;Nogareda F;Orenstein WA;Ortiz JR;Pebody R;Schrag SJ;Smith PG;Srikantiah P;Subissi L;Valenciano M;Vaughn DW;Verani JR;Wilder-Smith A;Feikin DR
通讯作者：
Feikin DR
影响因子：
82.9
作者：
Andrews, Nick;Stowe, Julia;Kirsebom, Freja;Toffa, Samuel;Sachdeva, Ruchira;Gower, Charlotte;Ramsay, Mary;Bernal, Jamie Lopez
通讯作者：
Bernal, Jamie Lopez